Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer’s Disease (P11-9.013)
Year: 2024
Type: article
Source: Neurology
Institutions: Amsterdam UMC Location Vrije Universiteit Amsterdam, Brigham and Women's Hospital, Harvard University, Banner Sun Health Research Institute, Banner Alzheimer’s Institute, University of California San Diego, Lund University, Skåne University Hospital, University of Copenhagen, Gentofte Hospital, Novo Nordisk Foundation Center for Basic Metabolic Research, Steno Diabetes Center Copenhagen, James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, Novo Nordisk (Denmark), University of Nevada, Reno
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4394599391